Fluid Biopsy Market Size
| Study Period | 2021 - 2030 |
| Base Year For Estimation | 2024 |
| Market Size (2025) | USD 7.11 Billion |
| Market Size (2030) | USD 15.20 Billion |
| CAGR (2025 - 2030) | 16.40% |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Fluid Biopsy Market Analysis
The Fluid Biopsy Market size is estimated at USD 7.11 billion in 2025, and is expected to reach USD 15.20 billion by 2030, at a CAGR of 16.4% during the forecast period (2025-2030).
COVID-19 had a significant impact on the fluid biopsy market during the pandemic period. The increasing developments of fluid biopsy in the diagnosis of COVID-19 are expected to contribute to the growth of the market. For instance, the article published in the JAMA network in March 2021 mentioned that researchers at Cornell University developed a "liquid biopsy" that detected and quantified injury to internal organs from the COVID-19 virus. This liquid biopsy test profiled epigenetic changes in circulating cell-free DNA-small fragments of genetic material from dead cells, including those killed off by infection or immune-related injury. Thus, such developments in liquid biopsy for the COVID-19 infection had a notable impact on the growth of the market during the pandemic period. Also, the demand for fluid biopsy is expected to remain intact during the post-pandemic period due to the increasing focus on various chronic and infectious diseases, thereby contributing to the growth of the market over the forecast period.
The market is expected to grow because there are more cases of cancer around the world and more people want non-invasive diagnostic procedures.
As per the World Health Organization fact sheet published in February 2022, in 2021, there were an estimated 1.9 million new cancer cases diagnosed in the United States. The report also mentioned that each year, approximately 400,000 children worldwide develop cancer estimated 1.9 million new cancer cases diagnosed in the United States. The report also mentioned that each year, approximately 400,000 children worldwide develop cancer. Cervical cancer is the most common in 23 countries, such as Eswatini, India, South Africa, Latin America, and others. The most common cancers are breast, lung, colon, rectum, and prostate cancers. Thus, the higher cases of cancer are generating demand for fluid biopsy due to its non-invasive diagnostic procedure, thereby contributing to the growth of the market.
Also, the market players' initiatives, such as partnerships, mergers, product launches, and product developments, are expected to boost the growth of the market. For instance, in December 2021, Epic Sciences Inc. launched DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw. Define MBC provides comprehensive MBC profiling when a tissue biopsy result is not available. Additionally, in March 2021, Sysmex Europe GmbH, in partnership with Sysmex Inostics GmbH, launched Plasma-SeqSensei liquid biopsy Research Use Only (RUO) kits for colorectal cancer, non-small cell lung cancer, melanoma, and thyroid cancer.
Thus, the rising cases of cancer across the world and innovative product developments are expected to contribute to the growth of the market. Over the next few years, however, the growth of the market is likely to be slowed by the growing popularity of alternative technologies like optical biopsies.
Fluid Biopsy Market Trends
Breast Cancer is Expected to Record Notable CAGR in the Market During the Forecast Period
A breast biopsy is the only diagnostic procedure that can determine if the suspicious breast area is cancerous. A breast biopsy test removes tissue or sometimes fluid from the suspicious area, and the removed cells are examined under a microscope and further tested to check for the presence of breast cancer. The increasing number of cases of breast cancer across various regions in the world along with the rising demand for innovative and non-invasive diagnostic procedures are expected to contribute to the growth of the studied segment.
For instance, as per the National Breast Cancer Foundation Inc., data published in June 2022 mentioned that in 2022, an estimated 287,500 new cases of invasive breast cancer will be diagnosed in women in the United States, as well as 51,400 new cases of non-invasive breast cancer. According to the report, an estimated 2,170 men will be diagnosed with breast cancer in the United States in 2022.Additionally, the MDPI article in July 2022 mentioned that 45.4% of breast cancer cases are diagnosed in Asian countries. Such a high prevalence of breast cancer across various regions worldwide is expected to drive demand for the fluid biopsy market, thereby fueling segment growth.
Also, the rising product developments by various market players in order to meet the growing demand for non-invasive fluid biopsy for breast cancer are expected to drive the growth of the studied segment. For instance, in June 2021, NeoGenomic Inc. unveiled new data in support of the RaDaR assay for the detection of minimal residual disease and recurrence in patients with high-risk hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer.
North America is Expected to Hold Significant Share in the Market over the Forecast Period
North America is expected to dominate the overall market during the forecast period owing to the rising cancer cases in this region along with rising research and developments. Additionally, the presence of key market players and frequent fluid biopsy product developments are also expected to contribute to the growth of the market. For instance, according to American Cancer Society Inc. data published in 2022, in 2021, there were an estimated 1.9 million new cancer cases diagnosed in the United States. In addition, according to the Public Health Agency of Canada data published in October 2021, approximately 2 in 5 Canadians were diagnosed with cancer in their lifetime, and in 2021, an estimated 229,000 Canadians were diagnosed with cancer. The report also mentioned that lung, breast, colorectal, and prostate cancers were expected to remain the most commonly diagnosed cancers, accounting for nearly 46% of all cancer diagnoses in 2021. Such a high prevalence of cancer in North American countries is expected to contribute to the growth of the market.
Additionally, rising funding activities from various organizations and increasing product approvals and developments by various market players are expected to contribute to the growth of the market in this region. For instance, in November 2021, BioMark Diagnostic Solutions received funding of up to CAD 169,500 (USD 123,474.78) from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support research and development of a liquid biopsy assay for the early detection and screening of lung cancer. Similarly, in May 2021, Lucence launched a United States Validation Study for the Liquid Hallmark liquid biopsy assay versus tissue biopsy in detecting guideline-recommended biomarkers in lung cancer.
So, the growth of the market in North American countries is likely to be driven by the rise of different types of cancer, the rise of funding activities, and the rise of new products.
Fluid Biopsy Industry Overview
The fluid biopsy market is competitive and consists of a few major players. In terms of market share, these players currently dominate the market. Some of the major players are Bio-Rad Laboratories, LungLife AI Inc. (Cynvenio), Guardant Health, Horizon Discovery, and Qiagen.
Fluid Biopsy Market Leaders
-
Bio-Rad Laboratories
-
Guardant Health
-
Horizon Discovery
-
Qiagen NV
-
LungLife AI Inc.
- *Disclaimer: Major Players sorted in no particular order
Fluid Biopsy Market News
- August 2022: Predicine launched the CE-Market Predicine CARE for PredicineCARE, a liquid biopsy for genomic profiling and is designed to target 152 genes in patients diagnosed with Cancer.
- July 2022: BillionToOne launched the oncology liquid biopsy products, North Select and Northstar Response. These products are currently available for research use at select academic cancer centers.
Fluid Biopsy Industry Segmentation
As per the scope of the report, fluid biopsy, also known as liquid biopsy or fluid phase biopsy, is a procedure of sampling and analyzing non-solid biological tissues (blood and others) for the screening of cancer and other inflammatory conditions associated with cardiac and other medical disorders. The Fluid Biopsy Market is segmented by Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, and Other Indications), Type (Circulating Tumor Cells, Circulating Tumor DNA, and Cell-free DNA), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Indication | Lung Cancer | ||
| Breast Cancer | |||
| Colorectal | |||
| Other Indications | |||
| By Type | Circulating Tumor Cells | ||
| Circulating Tumor DNA | |||
| Cell-free DNA | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Lung Cancer |
| Breast Cancer |
| Colorectal |
| Other Indications |
| Circulating Tumor Cells |
| Circulating Tumor DNA |
| Cell-free DNA |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Fluid Biopsy Market Research FAQs
How big is the Fluid Biopsy Market?
The Fluid Biopsy Market size is expected to reach USD 7.11 billion in 2025 and grow at a CAGR of 16.40% to reach USD 15.20 billion by 2030.
What is the current Fluid Biopsy Market size?
In 2025, the Fluid Biopsy Market size is expected to reach USD 7.11 billion.
Who are the key players in Fluid Biopsy Market?
Bio-Rad Laboratories, Guardant Health, Horizon Discovery, Qiagen NV and LungLife AI Inc. are the major companies operating in the Fluid Biopsy Market.
Which is the fastest growing region in Fluid Biopsy Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Fluid Biopsy Market?
In 2025, the North America accounts for the largest market share in Fluid Biopsy Market.
What years does this Fluid Biopsy Market cover, and what was the market size in 2024?
In 2024, the Fluid Biopsy Market size was estimated at USD 5.94 billion. The report covers the Fluid Biopsy Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the Fluid Biopsy Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Our Best Selling Reports
Fluid Biopsy Industry Report
Statistics for the 2025 Fluid Biopsy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Fluid Biopsy analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
